First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of shares of common stock Closed: US$200M raised · US$32.75 a share · Leerink Partners +3 Dealers: Leerink Partners, Piper Sandler, UBS Investment Bank, Wells Fargo Securities Buyers: Affinity Asset Advisors, LLC; First Light Asset Management; Sirenia Capital Management LP; TCGX; Trails Edge Capital Partners; Vestal Point Capital Use of proceeds: General corporate purposes, including clinical development of ANB033, a CD122 antagonist | Nov 3, 2026 |